Status:
COMPLETED
Tai Chi for Relieving Aromatase Inhibitor-Induced Arthralgia in Patients With Stage I-III Breast Cancer, the TaiChi4Joint Trial
Lead Sponsor:
Thomas Jefferson University
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
This trial studies new methods using Tai Chi for the relief of joint pain (arthralgia) caused by an aromatase inhibitor in patients with stage I-III breast cancer. Tai Chi is a mind-body therapy that ...
Detailed Description
PRIMARY OBJECTIVE: I. To evaluate the feasibility, acceptability, and preliminary efficacy of a 12-week Tai Chi intervention for relieving aromatase inhibitor (AI)-induced arthralgia in women with br...
Eligibility Criteria
Inclusion
- Be able to speak and read English
- Been diagnosed with stage I-III breast cancer (BC)
- Had completed all active treatments
- Had been receiving an AI (anastrozole, letrozole, or exemestane) for at least 3 months
- Had joint (knee, hand or hip) pain or stiffness that started or worsened after the initiation of AI
- Report worst pain in the past week \>= 4 on a 0-10 numeric rating scale
- Be willing to adhere to all study procedures
Exclusion
- Has been diagnosed with another form of cancer in the past 5 years
- Uncontrolled cardiac, pulmonary, or infectious disease
- Body mass index (BMI) \> 40 kg/m\^2
- Currently attending any mind-body therapy classes (e.g. yoga)
- Joint pain due to inflammatory arthritic condition (such as rheumatoid arthritis, osteoarthritis or gout, which will be assessed during eligibility screening with patient self-reported data and will be screened through electronic medical record \[EMR\] data)
- Had surgery or joint infection in the past 6 months
- Currently taking corticosteroids or opioids, have discontinued or plan to discontinue AI in the next 6 months
Key Trial Info
Start Date :
March 11 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 23 2021
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT04716920
Start Date
March 11 2020
End Date
December 23 2021
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107